Skip to content

Evaluation of the Potential Impact of an Artificial Intelligence Solution in Second Reading of Organized Screening.

Evaluation of the Potential Impact of an Artificial Intelligence Solution in Second Reading of Organized Screening.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06479772
Acronym
ELIAS
Enrollment
55589
Registered
2024-06-28
Start date
2023-10-10
Completion date
2024-03-31
Last updated
2024-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer Female

Brief summary

Based on data from a series of patients who underwent screening mammography with a normal or benign first-reading result. The main objective of the study is to evaluate the possibilities of subtracting from the second reading of breast cancer screening a population of examinations for which the risk of discovering cancer is close to zero, using an AI system (here the MammoScreen™ system).

Detailed description

This is a retrospective multicenter study of mammography imaging data contained in the PACS (Picture Archiving and Communication System) of six radiology centers located in the Rhône, Puy de dôme, Cantal and Haute-Loire départements. In order to be able to collect two-year follow-up data, the files analyzed will concern all women who received a screening mammogram during the years 2015, 2016, 2017, 2018 and 2019. More recent mammograms will be excluded.

Interventions

None listed

Sponsors

Vivactis M2Research
CollaboratorINDUSTRY
GCS Ramsay Santé pour l'Enseignement et la Recherche
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
50 Years to 74 Years
Healthy volunteers
Yes

Inclusion criteria

* Women aged 50 to 74 participating in the organized screening campaign. * Having had a screening mammogram with a final L1 result of normal (ACR 1/ BI-RADS 1) or benign (ACR 2/ BI-RADS 2). * For which a second reading interpretation is available * Screening mammograms performed during the years 2015 to2019 (In order to have follow-up data (subsequent mammogram or information on the person's future)

Exclusion criteria

\- Mammography not performed as part of organized screening

Design outcomes

Primary

MeasureTime frameDescription
Percentage of real negativesWeek 8Percentage of cases negatived by MammoScreen (considered benign by the system), and for which no cancer was detected at the end of the L2 (according to the different risk levels of the MammoScreen software - score from 1 to 10). We distinguish two sub-populations: L2- and L2+ with BDD- (in addition to L2-).

Secondary

MeasureTime frameDescription
Percentage of real positivesWeek 8Percentage of MammoScreen-positive cases for which cancer was detected in L2 (according to the different risk levels of the MammoScreen software - score from 1 to 10).
Percentage of false negativesWeek 8Percentage of MammoScreen-positive cases with an L2 ultimately considered negative (L2- or L2 + with DBB-), for which interval cancer is detected (according to the different risk levels of the MammoScreen software - score from 1 to 10).

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026